Daniel J. Lenihan – författare

This issue of the Heart Failure Clinics of North America, guest edited by Drs. Daniel Lenihan and Douglas Sawyer, will cover several aspects of Cardio-oncology Related to Heart Failure. Subjects discussed in the volume include, but are not limited to: Proteasome Inhibitors as a potential cause of Heart Failure; EGFR target based therapy; Amyloidosis; How to manage Heart Failure in a patient with cancer; Advanced HF/Txp; Epidemiology and common risk factors; Pediatric Considerations; Alternative biomarkers for combined biology; How to develop a Cardio-Oncology Clinic; and How to structure a Cardio-Oncology fellowship program, among others.

As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.� Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.� This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.

Written by experts in cardiovascular disease, hematology, and oncology, The Washington Manual® of Cardio-Oncology: A Practical Guide for Improved Cancer Survivorship is a clinically relevant, easy-to-use primer on the detection, management, and improved cardiovascular-based patient outcomes in adults undergoing treatment for cancer or who have previously survived cancer therapy. Edited by Drs. Daniel J. Lenihan, Joshua D. Mitchell, and Kathleen W. Zhang, this concise yet comprehensive manual provides high-yield information that reflects today’s advances in risk stratification, early diagnosis, and treatment of cardiovascular disease—all in an easy-access, concisely bulleted format for on-the-go reference. Discusses the multitude of complex adverse effects of chemotherapy, targeted therapy, immunotherapy, and radiation therapy to help optimize quality of life and prolong survival in this vulnerable patient population. Includes chapters on how cancer therapy affects the myocardium, valves, pericardium and cardiac electrical system including handy reference tables on typical side effects of commonly used cancer therapies.Provides practical guidance in an easy-to-follow format that covers definition, associated drugs/therapies, epidemiology, diagnosis (history, physical exam, and diagnostic testing), treatment, and outcome/prognosis.Covers the role of non-invasive imaging modalities in the diagnosis and screening for cardiovascular disease including echocardiography, MRI, and nuclear imaging.Addresses frequently encountered clinical scenarios such as preoperative or pre-high-risk treatment evaluation with up-to-date expert consensus recommendations.Details emerging treatments and optimal use of non-invasive imaging in cardiac amyloidosis.Features easy-to-use flow-charts and tables that aid in the differentiation of cardiac masses.The Washington Manual® is a registered mark belonging to Washington University in St. Louis to which international legal protection applies. The mark is used in this publication by Wolters Kluwer Health under license from Washington University. Enrich Your eBook Reading ExperienceRead directly on your preferred device(s),such as computer, tablet, or smartphone.Easily convert to audiobook,powering your content with natural language text-to-speech.

Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics:• Cardiac complications in patients receiving cancer therapy• The treatment of cancer in patients with cardiovascular disease• The treatment of cardiovascular disease in patients with cancerWhen relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.